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Interleukin-1 receptor antagonist halts the progression of established
crescentic glomerulonephritis in the rat. The pathogenic role of interleu-
kin-i (IL-I) in the progression of established rat crescentic glomerulone-
phritis was investigated by administration of the interleukin-1 receptor
antagonist (IL-ira). Passive accelerated antiglomerular basement mem-
brane (GBM) disease was induced in three groups of six rats. One group
was killed on day 7 with no treatment. The other groups received a
constant infusion of IL-Ira or saline from day 7 until being killed on day
21. All animals developed moderate glomerular injury, a significant loss of
renal function and marked histological damage including crescent forma-
tion by day 7. Saline treated animals showed a significant deterioration in
these parameters over days 7 to 21. In contrast, animals treated with the
IL-Ira over this period showed stabilization of glomerular injury (protein-
uria; P < 0.001) and a recovery of normal renal function (creatinine
clearance; P < 0.05). Histologically, IL-ira treatment suppressed glomer-
ular cell proliferation (PCNA expression; P < 0.001) and significantly
inhibited crescent formation (P < 0.005), glomerular sclerosis (P < 0.005),
tubular atrophy (P < 0.05) and interstitial fibrosis (P < 0.05). A key
finding was that IL-ira treatment not only stopped renal leukocyte
accumulation over days 7 to 21 (P < 0.01), but that treatment also
suppressed immune activation of the infiltrate (P < 0.01). In conclusion,
this study provides direct evidence that IL-i plays a key role in the
progressive/chronic phase of renal injury in experimental crescentic gb-
merulonephritis and indicates that IL-ira treatment may be of therapeutic
benefit in human rapidly progressive crescentic glomerulonephritis.
Interleukin-1 (IL-I) is a cytokine which elicits a wide range of
pro-inflammatory and immunologic effects, including: activation
of endothelium; stimulation of T and B cell activation; up-
regulation of leukocyte adhesion molecule expression by many
cell types; and the induction of a range of cytokines and growth
factors including interleukins 1, 2, 6 and 8, tumor necrosis
factor-a, monocyte chemotactic protein-i, platelet-derived
growth factor, and transforming growth factor-/3, which regulate
events such as leukocyte chemotaxis and the fibrotic response [1,
2]. A potential role for IL-i in proliferative forms of glomerubo-
nephritis was first suggested by studies in which macrophage-
derived IL-i was found to stimulate mesangial cell proliferation in
vitro [3]. Since then, renal IL-i production has been detected
during acute and progressive/chronic phases of experimental
[4—10] and human glomerulonephritis [11—13]. The main source
of renal IL-i production appears to be infiltrating macrophages
[5, 7, 10—13] which are a common feature of almost all forms of
human and experimental glomerulonephritis [14], although other
renal cell types such as mesangial cells and tubular epithelial cells
can also synthesize IL-i [12, 15].
To demonstrate a pathogenic role for IL-i in glomerulonephri-
tis it is necessary to block the action of IL-i in vivo. Such an
approach has been made possible by the identification and
characterization of a specific IL-i receptor antagonist (IL-ira) [1,
16, 17]. Initial studies using the IL-ira targeted acute glomerular
injury in rat anti-GBM glomerulonephritis which is mediated by a
transient glomerular neutrophil influx following deposition of
antibodies on the GBM [18—20]. IL-ira treatment during this
period had no discernible effect upon neutrophil influx or glomer-
ular injury. However, an important finding was that a 14 day
treatment with the IL-ira from the time of anti-GBM serum
injection produced a marked suppression of the monocyte-depen-
dent phase of glomerular injury and renal impairment [20].
Having demonstrated a key role for IL-i in the induction of
monocyte-dependent renal injury, the next question was whether
blocking IL-i could intervene in the progressive phase of estab-
lished crescentic glomerulonephritis. This is an important issue
because of its relevance to treatment of human disease and in
identifying pathogenic mechanisms of renal damage, as a range of
other mediators of renal injury are produced during the progres-
sive phase. Hence, this study examined the ability of IL-ira
treatment to intervene in the progression of established rat
anti-GBM glomerulonephritis.
Methods
Animals
Inbred male Sprague-Dawley rats (150 g) were obtained from
the Monash University Animal House.
Nephrotoxic serum
Rabbit anti-rat GBM nephrotoxic serum was raised by repeated
immunization of New Zealand white rabbits with particulate rat
GBM, as previously described [21]. The anti-GBM serum was
pooled, decomplemented and adsorbed extensively against nor-
mal rat eiythrocytes.
Experimental design
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Passive accelerated anti-GBM disease was induced in 18 rats as
previously described [20, 22, 23]. Animals were immunized sub-
cutaneously with 5 mg normal rabbit IgG in Freund's complete
adjuvant and injected intravenously with 10 ml/kg body weight
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Time, days after administration of nephrotoxic serum
rabbit anti-rat GBM serum (12.5 mg IgG/ml) five days later
(termed day 0). One group of six rats was killed on day 7 with no
treatment. The remaining animals received a constant infusion of
either human recombinant IL-Ira (Synergen, Colorado, USA) or
saline from day 7 until being killed at day 21 by means of an Aizet
2002 miniosmotic pump implanted under the skin of the back
which delivered 0.5 1ii/hr of 50 mg/mI IL-ira in saline. Following
pump implantation, all wounds healed cleanly and there were no
signs of infection when pumps were removed at the end of the
experiment.
Blood samples and 24-hour urine collections were taken on
days 0, 7, 14, and 21. Plasma levels of hrIL-lra were measured by
a commercial ELISA (R&D Systems, MN, USA) and were 671
175 ng/ml (mean SEM) on day 14 and 643 112 nglml on day
21. In addition, one group of six normal rats was also examined.
Analysis of renal function and proteinuria
Urinary protein excretion was determined using the Manual
Ponceau Red method. Urinary blood (hematuria) was determined
by a standard Combur's stick test (Boehringer Mannheim) and
semi-quantitated into four scores: (1) trace or minor, (2) mild, (3)
moderate, and (4) severe. Concentrations of plasma and urine
creatinine were measured using the standard Jaffe rate reaction
(alkaline picrate), while plasma urea concentrations were mea-
sured by the NED/OPA assay. All analyses were performed in the
Department of Biochemistry, Monash Medical Centre.
Immunofluorescence
Tissues for direct immunofluorescence staining were frozen in
liquid nitrogen and 6 m cryostat sections were stained with
fluorescein isothiocyanate (FITC)-conjugated goat polyclonal an-
tibodies to rat IgG, C3 and fibrinogen or FITC-conjugated sheep
anti-rabbit IgG (Nordic, the Netherlands). The intensity of anti-
body staining was semi-quantitatively assessed as: nil (0), mild
(+), moderate (++), and strong (+++). In addition, day 21
tissues were assessed for deposition of immune reactants by
Fig. 1. Suppression of renal injuly by IL-Ira
treatment. Data for (A) 24-hour urinary protein
excretion, (B) plasma urea levels, (C) plasma
creatinine levels, and (D) ereatinine clearance
are shown. Symbols are: saline treated animals
(.-), IL-ira treated animals (--0--) . Data are
expressed as the mean SEM for each
experimental group of 6 animals. Untreated
animals killed on day 7 of anti-GBM disease
had proteinuria of 228 25 mg124 hr, plasma
urea of 18.5 1.2 mmol/liter, plasma creatinine
of 72.5 5.8 mol/liter, and ereatinine
clearance of 0.57 0.08 mI/mm. Statistical
differences between untreated and IL-Ira
treated groups was assessed by one way analysis
of variance (ANOVA); * P < 0.05, ** P <
0.001.
semi-quantitative immunofluorescence staining using a blinded
antibody titration method as previously described [23]. Briefly,
consecutive cryostat sections from each animal were incubated
with serial dilutions of FITC-conjugated antibodies against rabbit
IgG, rat lgG or rat C3 Blinded sections were examined on the
same day and the titer at which antibody staining became unde-
tectably scored. Results are expressed in terms of mean SEM of
the inverse antibody titer for groups of six animals.
Measurement of plasma antibodies
Plasma levels of rabbit IgG, rat anti-rabbit IgG, rat anti-human
rIL-Ira IgG and total rat IgG were determined by capture ELISA
as previously described [231. Briefly, 96-well ELISA plates were
coated with 100 l of swine anti-rabbit 1gG, normal rabbit IgG,
human recombinant IL-ira or normal rat IgG (10 rg/ml in 0.1 M
carbonate-bicarbonate buffer, pH 9.0) overnight at 4°C, blocked
with 2% bovine serum albumin and washed (X4) with 0.05%
Tween 20 in PBS. Triplicate serum samples (1:1000 dilution) were
added to wells, incubated for two hours and washed (X4) with
0.05% Tween 20 in PBS. Bound rabbit or rat IgG was detected
using a peroxidase-conjugated sheep anti-rabbit IgG or peroxi-
dase-conjugated sheep anti-rat lgG (Sigma Chemical Co., St.
Louis, MO, USA) and color development with the OPD substrate
for 10 minutes in the dark. The reaction was terminated with 3 M
H2S04 and optical density (OD) was read at 490 nm on a Dynatec
MR 5000 ELISA plate reader. The background reading obtained
with normal rat serum, which was the same as the buffer blank,
was subtracted from the readings, except for measurement of total
rat IgG when the buffer blank was subtracted.
Histopathology
Tissues for histology were fixed in formalin and 4 tm paraffin
sections were stained with hematoxylin and eosin or periodic
acid-Schiff. Glomerular and tubulointerstitial damage was scored
as follows: the percentage of glomeruli exhibiting atrophy/seg-
mental sclerosis, global sclerosis or glomerular crescent formation
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was assessed by examination of at least 100 glomerular cross
sections per animal in periodic acid-Schiff-stained sections. Gb-
merular hypercellularity was assessed on the basis of total glomer-
ular cell counts/glomerular cross section (gcs). At least 100
gbomeruli per animal were scored in hematoxylin and eosin-
stained sections and ranked as follows: (0), normal (less than 50
cells/gcs); (1), mild (60 to 80 cells/gcs); (2), moderate (80 to 120
cells/gcs); (3), severe hypercellularity (more than 120 cells/gcs).
Tubulointerstitial lesions of tubular atrophy and fibrosis were
semi-quantitatively analyzed on hematoxylin and eosin-stained
sections and graded on a scale of 0 to 3 as follows: (0) no apparent
damage; (1) mild damage, with lesions involving less than 15% of
the cortex; (2) moderate damage, involving 15 to 30% of the
cortex; and (3) severe damage, that is, involving more than 30% of
the cortex and focal accumulation of leukocytes at sites of
damage.
Immunoperoxidase staining
Monoclonal antibodies (mAb) used for immunoperoxidase
staining were as follows: OX-i, leukocyte common antigen [24];
ED1, monocytes, macrophages and some dendritic cells [25]; R73,
non-polymorphic a13 T cell receptor [26]; OX-8, anti-rat CD8,
cytotoxic T lymphocytes and NK cells [27]: F17-23-2, MHC class
lila antigen (RT1-B) [28]; NDS-61, p55 chain of the interleukin-2
receptor (IL-2R) [29]; PC-b, proliferating cell nuclear antigen
(PCNA) [30].
Tissues for immunoperoxidase staining were fixed in 2%
paraformaldehyde-lysine-periodate and serial 6 j.m cryostat sec-
tions were labeled with monoclonal antibodies (mAbs) using a
standard three layer peroxidase-anti-peroxidase method and de-
veloped with diaminobenzidine as previously described [20, 22].
Three layer immunoperoxidase staining with the PC-lO mAb was
performed on cryostat tissue sections which were pre-treated with
microwave oven heating for 2 X 5 minutes in 0.01 M sodium
citrate pEl 6.0 at 800 watts as previously described [31, 32]. This
treatment facilitates antigen retrieval, thereby increasing the
sensitivity of PCNA detection.
Quantitation of leukocytes in tissue sections
Leukocyte subpopulations infiltrating the glomerulus and inter-
stitium were analyzed by mAb labeling of cryostat tissue sections.
Cells labeled by each mAb were counted in high power fields
(x400) of 20 consecutive glomeruli for each animal (this mini-
mized variation in cell counts caused by differences in glomerular
cross section areas). The mean of 20 glomerular counts from each
group of six animals was expressed as cells standard error of
mean (sEM) per glomerular cross section. To assess tubulointer-
stitial leukocyte infiltration, cortical areas were selected at ran-
dom. The number of labeled cells was assessed from 20 consecu-
tive high power fields by means of a 0.02 mm2 graticule fitted in
the eyepiece of the microscope. These fields progressed from the
outer to inner cortex, avoiding only large vessels, glomerular and
immediate periglomerular areas. For each tissue, the same area
was examined in serial sections labeled with different mAbs. No
adjustment of the cell count was made for tubules or the luminal
space. The mean of 20 field counts from each group of six animals
was expressed as cells per mm2 SEM.
Scoring of histological changes, immunofluorescence and im-
munoperoxidase staining was performed on coded slides by an
experienced renal pathologist (HYL).
Statistical analysis
Data from the measurement of renal function and proteinuria
over the experimental course were analyzed using the one way
analysis of variance (ANOVA) program from Complete Statisti-
cal System (CSS, Statsoft, USA), and individual time points were
also compared using the unpaired t-test. Data from leukocyte
infiltration in the two renal compartments was compared using an
unpaired t-test. Measurements of hematuria and histological
changes were compared by the non-parametric Mann-Whitney U
test.
Results
Renal firnction and proteinuria
On day 7 of anti-GBM disease, all animals exhibited moderate
proteinuria, a significant increase in plasma levels of creatinine
and urea, and a 37% reduction in creatinine clearance (Fig. i).
Over days 7 to 21 there was a significant deterioration in saline
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Fig. 2. Effect of IL-ira treatment on the plasma antibody levels. Plasma
levels of (A) rabbit IgG, and (B) rat anti-rabbit IgG, were quantitated at
different times by ELISA. Symbols are: saline treated animals (*) ; IL-ira
treated animals (--0--). Data are expressed as the mean optical density
(OD490) SEM for each group of 6 animals with background subtracted.
Untreated animals killed on day 7 had 0.85 0.04 and 0.04 0.05 OD490
plasma rabbit IgG and 0.05 0.05 and 0.44 0.13 OD490 plasma rat
anti-rabbit IgG on days 1 and 7, respectively.
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Table 1. Inhibition of histopathological damage by IL-ira treatment
Tubulointerstitium
Crescents Atrophy Fibrosis
% (0—3) (0—3)
treated animals which developed severe proteinuria, a further
increase in plasma levels of creatinine and urea, while creatinine
clearance remained impaired (Fig. 1). This is consistent with
previous studies in this model in which a very similar disease
progression was evident in untreated animals over this time course
[22, 23].
IL-ira treatment over days 7 to 21 prevented the increase in
proteinuria seen in saline treated animals, stabilized plasma
creatinine and reduced plasma urea to normal levels (Fig. 1). Of
particular note was the finding that IL-ira treatment produced a
gradual recovery to a normal rate of creatinine clearance (Fig.
ID).
On day 7 of anti-GBM disease, all animals exhibited moderate
to severe hematuria (2.3 0.8). In saline treated animals, there
was an increase in hematuria over days 7 to 21(3.0 0.4 on day
21). However, IL-ira treatment resulted in a marked improve-
ment in hematuria with all animals showing only trace to mild
hematuria on day 21(1.0 0; P < 0.05 vs. saline treated).
Deposition of immune reactants
Deposition of immune reactants within the kidney was assessed
by direct immunofluorescence staining of cryostat tissue sections.
In untreated animals killed on day 7 of anti-GBM disease, there
was strong (+ + +) linear deposition of rabbit IgG and moderate
(+ +) linear deposition of rat IgG, and C3 along the GBM. In
addition, moderate (+ +) fibrinogen deposition was seen within
Bowman's space in some glomeruli and within the interstitium. At
day 21, saline treated animals exhibited strong (+ + +) linear
deposition of rabbit IgG, rat IgG and C3 along the GBM. There
was also a strong patchy deposition of fibrinogen, rat lgG and C3
within Bowman's space, crescents and necrotic glomerular capil-
lary tufts and strong fibrinogen deposition throughout the inter-
stitium.
The effect of IL-Ira treatment on the intensity of immune
deposits on the GBM on day 21 of anti-GBM disease was assessed
by a serial dilution immunofluorescence technique as described in
the Methods section. There was no difference in the intensity of
rabbit IgG deposition on the GBM in saline treated and IL-ira
treated animals (12000 1454 vs. 12800 1905; mean inverse
antibody titer SEM, respectively). Similarly, there was no differ-
ence in the intensity of rat IgG deposition (900 73 vs. 940 39)
or C3 deposition (4800 762 vs. 3290 953) in saline and IL-Ira
treated animals, respectively. However, IL-Ira treated animals
showed little, if any, deposition of rat IgG, C3 and fibrinogen
within Bowman's space and had only mild (+) fibrinogen depo-
sition throughout the interstitium.
Quantitation of plasma antibody titers by ELISA was per-
formed to check that all animals received an equivalent dose of
rabbit anti-GBM serum and to examine whether IL-ira treatment
had any suppressive effect on the humoral immune response.
Figure 2A shows that high plasma levels of rabbit IgG were still
evident 24 hours after injection of anti-GBM serum and had
almost disappeared by day 7. There was no difference in plasma
rabbit IgG levels in any of the experimental groups. The time
course of the rat anti-rabbit IgG response is shown in Figure 2B.
Rat anti-rabbit IgG was detected on day 1 reflecting the fact that
these animals were primed with rabbit IgG. There was a fourfold
increase in rat anti-rabbit IgG levels on day 7 and the response
remained at this level to day 21. No differences in rat anti-rabbit
IgG levels were apparent between the saline and IL-ira treated
groups. Similarly, there was no difference in plasma levels of total
rat IgG on day 21(0.566 0.017 vs. 0.577 0.024 0D490 in saline
and IL-ira treated animals respectively; P = NS). Of note was a
small antibody response to the administered human IL-ira on day
21(0.013 0.004 0D490) which was absent in saline treated
animals.
Histopathology
A detailed evaluation of renal histopathology was made on all
three groups of animals (Table 1). On day 7 of anti-GBM disease,
untreated animals displayed significant renal lesions. These un-
treated animals exhibited mild to severe hypercellularity in 60% of
glomeruli and there was marked glomerular cell proliferation as
assessed by PCNA expression (12.8 1.2 vs. 2.0 1.8 PCNA
cells/gcs in normal rats; P < 0.01). Segmental glomerular sclerosis
and crescent formation were also evident on day 7 of disease as
was mild tubular atrophy and fibrosis (Table I). In saline treated
animals, there was a pronounced deterioration in renal histopa-
thology by day 21 of the disease. Both the percentage and severity
of glomerular hypercellularity increased while the number of
PCNA glomerular cells remained high. In addition, there was a
marked increase in glomerular segmental and global sclerosis and
crescent formation as well as severe tubular atrophy and fibrosis.
Renal histopathology changes between IL-ira and saline treat-
ment animals at day 21. IL-ira treatment essentially halted
deterioration of renal histopathology over the days 7 to 21 period
(Table 1). The percentage of hypercellular glomeruli and the
severity of glomerular hypercellularity was similar in IL-Ira
Hypercellularity %
Glomerulus
+ ++ +++
Sclerosis %PCNA ____
cell/gcs Segmental Global
Untreated 25.3 2.4 24.5 1.6 10.3 1.5 12.8 1.2 21.0 3.8 0.6 0.2 14.0 3.2 1.2 0.2 1.5 0.2
Day 7
Saline 16.7 3.2u 44.5 3.6" 29.5 6' 12.0 0.9 49.0 5.1" 13.8 5.8" 58.5 4.9" 2.8 0.2 2.7 02'
treated
Day 21
IL-Ira 18.2 l.4' 25.0 35b 13.5 2.3 5.8 0.6c 24.5 3.6a 3.2 1.1l 25.0 4.0" 1.3 0.2" 1.5 0.2
treated
Day 21
"P < 0.05, "P < 0.005, compared to untreated day 7 animals, C P < 0.001, compared to saline treated day 21 animals
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Fig. 3. Suppression of renal leukocytic infiltration and immune-activation by
IL-Ira treatment. Total leukocytes and leukocyte subsets were analyzed by
labeling serial tissue sections with mAbs. Abbreviations are: OX-i, total
leukocytes; ED1, macrophages; R73, total T cells; F.17.23.2, MHC class II
I-A antigen; NDS 61, IL-2R. (a) Quantitation of leukocyte infiltration in
the glomerulus. (b) Quantitation of leukocyte infiltration in the tubuloin-
terstitium. Data are expressed as the mean SCM for each group of 6
animals. Open bars represent untreated day 7 anti-GBM disease. Closed
bars represent day 21 saline treated animals. Hatched bars represent day
21 IL-ira treated animals. Data for antibody labeling of normal rat
glomeruli are as follows: 0.94 0.10 OX-I cells/gcs; 0.76 0.10 ED1
cells/gcs; 0.34 0.10 R73 cells/gcs; 1.1 0.2i F.i7.23.2 cells/gcs; 0
0NDS 61 + cells/gcs. Data for antibody labeling of normal rat interstitium
are as follows: 99.4 10.2 OX-i cells/mm2; 26.0 1.4 EDiT cells/mm2;
31.4 6.7 R73 cells/mm2; 99.0 7.0 F. 17.23.2k cells/mm2; 0 0 NDS
6i cells/mm2. Statistical differences between the different groups was
assessed by unpaired t-test: * P< 0.05, ** P < 0.01, " P < 0.001, or not
significant (NS).
treated animals at day 21 and untreated animals at day 7, while
glomerular cell proliferation was markedly inhibited by IL-ira
treatment (Table 1). Glomerular segmental and global sclerosis
and crescent formation were not different in IL-ira treated
animals compared to untreated animals at day 7. Similarly,
tubular atrophy and interstitial fibrosis were also unchanged. An
example of histological damage in an IL-ira treated animals is
shown in Figure 3b.
Glomerular leukocytic infiltration
Renal leukocytic accumulation and immune activation was
examined by mAb labeling of cryostat tissue sections. There was a
prominent glomerular leukocyte infiltrate on day 7 of anti-GBM
disease (11.4 1.3 vs. 1.1 0.2 OX-1 cells/gcs in normal rats;
P < 0.001) which was composed of ED1 macrophages (Fig. 3a).
There was no significant increase in glomeruli R73 T cells (Fig.
3a) or CD8 cells (0.53 0.1 vs. 0.24 0.1 CD8 cells/gcs in
normal; P = NS), although there was an increase in the number of
CD4 cells (3.47 0.3 vs. 0.56 0.12 CD4 cells/gcs in normal;
P < 0.05) which presumably reflects a subpopulation of CD4
macrophages. There was also a significant increase in the number
of glomerular cells expressing MHC class II antigens (5.1 0.6 vs.
1.2 0.2 MHC class II cells/gcs in normal rats; P < 0.05) which
may be "activated" macrophages or mesangial cells.
In saline treated animals, there was no significant change in the
pattern of glomerular leukocytic infiltration or MHC class II
expression over days 7 to 21 (Fig. 3a). However, IL-ira treatment
over this period significantly reduced glomerular macrophage
infiltration in comparison to saline treated animals (Fig. 3a).
Interstitial leukocytic infiltration
The composition of interstitial leukocytic infiltration was differ-
ent to that seen in the glomerulus (Fig. 3). On day 7 of anti-GBM
disease there was a significant interstitial leukocyte infiltrate (735
81 vs. 102 16 OX-1 cells/mm2 in normal rats; P < 0.001)
which was composed of both EDI macrophages and R73 T
cells. There was evidence of immune activation of the mononu-
clear cell infiltrate as shown by interleukin-2 receptor (IL-2R)
expression and the prominent accumulation of MHC class II
cells within the interstitium (Fig. 3b). The T cell infiltrate con-
tained both CD8 cells (109 8.5 at day 7 vs. 38.0 8.0 CD8
cells/gcs in normal; P < 0.05) and CD4 cells (570.5 94 vs. 92.0
23.8 CD4 cells/gcs in normal; P < 0.01), although many
macrophages also expressed the CD4 antigen.
There was a significant increase in the number of interstitial
ED1 macrophages and R73 T cells in saline treated animals
over days 7 to 21. Of particular note was the marked increase in
the number of immune-activated mononuclear cells—both IL-
2R cells (1283%) and MHC class II cells (1 111%)—during
this period. Many of these activated cells were seen in focal
infiltrates of T cells and macrophages around and within damaged
tubules and immediately adjacent to areas of Bowman's capsule
rupture. However, there was no change in the number of CD8
cells (109 8.5 at day 7 vs. 103 9.4 CD8 cells/mm2 at day 21;
P = NS) while the number of CD4 cells was increased (570.5
94 at day 7 vs. 846.5 41 CD4 cells/mm2 at day 21; P < 0.01).
This indicated that the increased number of R73 T cells seen in
saline treated animals was due to accumulation of CD4 T cells.
IL-ira treatment completely stopped interstitial leukocyte ac-
cumulation and immune activation over the 7 to 21 day period
(Fig. 3b). The suppression of aggressive focal leukocytic infiltrates
was associated with a marked reduction in tubular damage and
interstitial fibrosis.
Discussion
This study has evaluated the effect of IL-Ira treatment on the
progression of established rat accelerated anti-GBM disease—a
severe model of glomerulonephritis which exhibits many features
similar to that of human rapidly progressive glomerulonephritis.
In this model, significant glomerular injury, renal function impair-
ment and histological damage was evident on day 7 which rapidly
progressed to a severe form of crescentic glomerulonephritis by
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day 21. IL-ira treatment over days 7 to 21 halted the progression
of established disease as demonstrated by: (i) stabilization of
proteinuria and reduction of hematuria, (ii) reversal of renal
function impairment, and (iii) inhibition of renal histopathologi-
cal damage. The ability of IL-ira treatment to intervene and halt
disease progression in this model demonstrates a key pathogenic
role for IL-i in crescentic glomerulonephritis. Indeed, the ability
to halt disease progression by targeting just one cytokine is most
impressive considering that a range of other cytokines and
mediators of renal injury are also produced during the disease
process [33]. This argues that the cytokine network in vivo
operates in an interdependent fashion rather than exhibiting
functional redundancy as suggested by their many overlapping
functions in vitro.
The suppression of rat anti-GBM disease by IL-ira treatment
indicates that IL-i acts at several levels in disease pathogenesis.
Possible mechanisms of IL-ira mediated suppression of disease
progression are discussed below.
T cells and macrophages play a crucial role in the induction and
progression of experimental anti-GBM disease [22, 34—38]. Gb-
merular macrophages are associated with glomerular hypercellu-
larity, crescent formation and glomerulosclerosis, while in the
interstitium aggressive focal accumulation of activated T cells
(IL-2R+) and macrophages is associated with tubular atrophy,
Bowman's capsule rupture, granuloma formation and interstitial
fibrosis. This disease is different to the NK (CD8) cell-depen-
dent anti-GBM disease induced in the susceptible WKY rat strain
[39], as it features a progressive accumulation and activation of
CD4 T cells within the interstitium, while CD8 cell numbers do
not change during disease progression over days ito 21 [22]. The
ability of IL-ira treatment of established anti-GBM disease to
reduce glomerular macrophage accumulation compared to saline
treated animals and to completely halt interstitial T cell and
macrophage accumulation and activation over this period was
associated with the stabilization of gbomerular injury and the
cessation of histological damage. This suppression of leukocyte
infiltration and activation is consistent with previous studies in
which IL-ira treatment prevented the developmeat of glomerular,
and in particular, interstitial leukocyte infiltration during the
induction phase of rat anti-GBM disease by suppressing up-
regulation of renal ICAM-1 (CD54) expression [20, 401.
Glomerular hypercellularity is a feature of proliferative forms
of glomerulonephritis and results from an increased number of
mesangial cells and glomerular leukocyte infiltration [411. The use
of double immunohistochemistry staining has demonstrated that
most glomerular PCNA cells detected in human and experimen-
tal models of glomerulonephritis are proliferating inesangial cells
[41, 42]. In our study, IL-ira treatment appeared to suppress
glomerular hypercellularity through inhibition of mesangial cell
proliferation as evidenced by the marked reduction in the number
of glomerular PCNA cells. This could be a direct effect since
IL-i is a mesangial cell growth factor in vitro [3]. However, IL-ira
treatment could also act indirectly through suppression of pro-
duction of other mesangial cell growth factors such as IL-6 or
platelet-derived growth factor (PDGF) by mesangial cells or
infiltrating macrophages [31, 43].
One further mechanism by which blocking IL-i action could
inhibit rat anti-GBM disease is through modulation of the hu-
moral immune response. In this model, there is a strong systemic
immune response to the immunizing rabbit IgG and the subse-
quent challenge with rabbit nephrotoxic serum [44]. Semi-quan-
titative immunofluorescence staining found that IL-ira treatment
had no affect upon the deposition of rabbit IgG, rat IgG or C3 on
the GBM. In addition, IL-ira treatment had no measurable effect
upon plasma levels of rat anti-rabbit IgG antibody throughout the
disease course. Thus, blocking IL-i did not affect the systemic
humoral immune response. Indeed, a mild antibody response to
the administered human IL-ira was detected, consistent with a
report that the IL-ira does not inhibit antigen specific responses
in vivo [45].
Further studies of established experimental crescentic glomer-
ulonephritis are warranted to determine: (1) whether disease
remains suppressed when IL-ira treatment is stopped, and (2)
how rapidly IL-ira treatment is able to halt disease progression.
In conclusion, this study provides the first direct evidence that
IL-i plays a key pathogenic role in the progressive/chronic phase
of renal injury in experimental crescentic glomerulonephritis. This
study also demonstrates the therapeutic potential of the IL-ira for
treatment of human rapidly progressive glomerulonephritis.
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